Impact of IL-9 and IL-33 in mast cells

G. Sabatino, M. Nicoletti, G. Neri, A. Saggini, M. Rosati, F. Conti, E. Cianchetti, E. Toniato, M. Fulcheri, A. Caraffa, P. Antinolfi, S. Frydas, F. Pandolfi, G. Potalivo, R. Galzio, P. Conti, T.C. Theoharides

Article ID: 6167
Vol 26, Issue 4, 2012
DOI: https://doi.org/10.54517/jbrha6167
Received: 8 January 2013; Accepted: 8 January 2013; Available online: 8 January 2013; Issue release: 8 January 2013

Abstract

Cytokines serve as chemical communicators from one cell to another and most of them have pro-inflammatory activity. Mast cells have been recognised as important mediators of the pathogenesis of allergy and inflammation, suggesting a role for IL-33-mediated mast cell activation. IL-33 was recently identified as a ligand for the orphan IL-1 family receptor T1/ST2 and is mainly expressed by mast cells, fibroblasts, epithelial cells, and endothelial cells, particularly in high endothelial venules. IL-33 is a potent inducer of pro-inflammatory cytokines such as IL-1, IL-6, IL-13 and TNF, and chemokines (MCP-1), by mast cells. Substance P is capable to induce VEGF from mast cells, and IL-33, the newest pro-inflammatory member of the IL-1 cytokine family, augments the effect of SP in VEGF transcription and translation protein. IL-9 is a pleiotropic and is expressed by multiple T helper (TH) cell subsets. IL-9 promotes the expression of mast cell pro-inflammatory cytokines in vitro and is involved in Th2 responses. This article focuses on recent developments of mast cells, IL-9 and IL-33, and recent literature and investigations were reviewed.


Keywords

IL-9;IL-33;mast cell;inflammation


References

Supporting Agencies



Copyright (c) 2012 G. Sabatino, M. Nicoletti, G. Neri, A. Saggini, M. Rosati, F. Conti, E. Cianchetti, E. Toniato, M. Fulcheri, A. Caraffa, P. Antinolfi, S. Frydas, F. Pandolfi, G. Potalivo, R. Galzio, P. Conti, T.C. Theoharides




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).